// App-Quantinova.ai

DOP019 : Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn’s disease: a GEMINI 2 post hoc analysis

Researchers

Presenter

  • B.G. Feagan

Principal Investigators

  • W.J. Sandborn

  • J.-F. Colombel

  • S. OByrne

  • J.M. Khalid

  • N. Brayshaw

  • P. Geransar

  • D.T. Rubin

Medical Centers

  • Robarts Research Institute, University of Western Ontario, Clinical Trials, London, ON, Canada

  • Univeristy of California San Diego, Division of Gastroenterolgy, San Diego, United States

  • Icahn School of Medicine at Mount Sinai, Department of Health Evidence and Policy, New York, United States

  • Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland

  • Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

  • Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom

  • Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland

  • University of Chicago Medical Center, Section of Gastroenterology, Hepatology and Nutrition, Chicago, United States

Locations

  • Canada

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00783692

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved